Bennett Eye Institute and Dr. Farhad Safi became the first ophthalmology practice and physician in Hawaii to perform a procedure using the FDA approved DURYSTA™ bimatoprost implant for glaucoma patients.
Dedicated to bringing the most advanced technology to the patients of Hawaii, Bennett Eye Institute and Dr. Farhad Safi became the first ophthalmology practice and physician in Hawaii to perform a procedure using the FDA approved DURYSTA™ bimatoprost implant for glaucoma patients. DURYSTA is the first of its kind, aimed to reduce intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT) using a sustained-release system.
“Today’s FDA approval marks a breakthrough milestone for the glaucoma community and provides a much-needed option for patients challenged with topical drops or needing alternative options,” said David Nicholson, Chief Research and Development Officer at Allergan, the maker of DURYSTA.
Known as the “silent thief of sight,” glaucoma impacts millions of people every year. Most forms of glaucoma are associated with high intraocular pressure (IOP), but the disease can also develop in people with normal or low eye pressure. Believed to lower intraocular pressure by 30%, the DURYSTA implant provides continuous drug delivery, reducing or completely eliminating the need for eye drops, a traditional therapy for many patients but one that comes with high costs and inconvenience.
DURYSTA is meant for patients with mild to moderate glaucoma. To learn more about the DURYSTA implant procedure and other services provided at Bennett Eye Institute, please send an email to Anu Nullar at anullar@bennetteyeinstitute.com or call (808) 955-0255.
